A recently released study at the San Antonio Breast Cancer Symposium claims that a few of the newly developed hormone medications are linked with increased risk of heart diseases and mainly linked with tamoxifen.

The study involved lead researcher Dr. Eitan Amir of the Princess Margaret Hospital in Toronto and his team tested tamoxifen separately with seven aromatase inhibitors in approximately 30,000 patients.

It was found that patients who made use of the aromatase inhibitors are nearly 26 percent more prone to develop heart diseases.

"Treatment with aromatase inhibitors is associated with a significant increase in the risk of cardiovascular events, specifically heart attacks, angina, and heart failure, compared with tamoxifen," Amir tells WebMd.

And at the same time in actuality the total number of women who suffered with a heart condition were seemingly lower than four percent. Amir adds that post-menopausal women who suffer from breast cancer should prohibit the over usage of aromatase inhibitors.

"Starting with tamoxifen and then switching to an aromatase inhibitor after several years -- rather than starting with an aromatase inhibitor and staying on it -- may reduce the risk of dying from causes other than breast cancer," he says. "But this is just a hypothesis at this point."